<DOC>
	<DOCNO>NCT01822925</DOCNO>
	<brief_summary>To evaluate effectiveness DA-9801 300mg , 600mg , 900mg placebo , reduce pain subject diabetic neuropathic pain compare baseline value .</brief_summary>
	<brief_title>Study DA-9801 Treat Diabetic Neuropathy</brief_title>
	<detailed_description>This double-blind , randomize , parallel group , dose range , placebo-controlled study eligible subject ( age 18 75 year ) average pain score ≥ 4 11-point Likert numerical rating scale ( NRS ) least four day week prior randomization assess daily pain diary . Eligible subject randomize 1:1:1:1 ratio receive 300mg , 600mg , 900mg DA-9801 , placebo three time day 12 week . During end 12-week treatment period subject evaluate safety efficacy parameter . A follow-up visit safety occur two week last treatment visit ( TV ) . The Screening Phase ( 2 week ) design determine whether subject eligible proceed Treatment Phase study consist series screen assessment design determine eligibility . Eligible subject undergo two-week washout period medication therapy administer pain management . At 21 day Screening Visit , write informed consent ( ICF ) subject obtain Investigator suitably qualify designee performance protocol specific procedure . At Screening Visit , subject issue daily diary order record daily pain level screen phase . The Treatment Phase ( TV0 TV12 ) begin series assessment design confirm subject ' continue eligibility . The site collect daily diary subject 's pain score determine . Only subject whose average pain score ≥ 4 least four day week randomize four treatment group . DA-9801 administration schedule three time per day , start TV0 TV12 . During study phase subject evaluate weekly basis . Efficacy evaluation week include subject 's global impression improvement CGI pain . Safety evaluation Treatment Phase consist adverse event assessment visit . The Follow-up Visit ( two week last TV ) The Follow-up Visit design assess safety occur 14 day last TV . If subject withdrawn study prior TV12 , subject exit study AFTER complete specify assessment visit .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Must 18 75 year age Diagnosed Type I Type II diabetes HbA1c ≤ 12 % time screening Has diabetic neuropathic pain ( numbness , soreness , shoot poke pain ) low extremity 3 month prior screen adequate relief treatment Has average pain score ≥ 4 24 hour least 4 day week prior randomization assess 11point Likert NRS . If female childbearing potential , subject must negative serum pregnancy test screen Understands willing participate clinical study comply study procedures visit . Normal cognitive communicative ability judge clinical assessment ability complete selfreported questionnaire Subject willing able give inform consent Evidence another type neuropathic pain cause condition diabetes Pain another source severe great pain study BMI ( Body Mass Index ) &gt; 37 kg/m2 Clinical sign infection relate sore type legs Subjects investigational drug ( ) therapeutic device ( ) within 30 day precede screening ; subject physician anticipate use therapy subject course study Previous participation Treatment Phase Protocol History drug alcohol abuse , within past 6 month Malignant disease remission 5 year medically surgically treat without evidence metastasis Presence one medical condition , determine medical history , seriously compromise subject 's ability complete study , include history poor adherence medical treatment , renal , hepatic , hematologic , active autoimmune immune disease , opinion Investigator , would make subject inappropriate candidate study : c ) One abnormal blood biochemistry analyte result ≥ 3 time upper limit normal range ; ) For laboratory result significantly low normal range , specific criterion use judge subject eligibility randomization Total protein , Albumin , Hemoglobin Platelets . Known history Acquired Immunodeficiency Syndrome ( AIDS ) history know infected Human Immunodeficiency Virus ( HIV ) New York Heart Association ( NYHA ) Class III IV congestive heart failure ( CHF ) , define follow criterion : ) Class III : Symptoms moderate exertion b ) Class IV : Symptoms rest Pregnant breast feed Women childbearing potential use effective birth control method . Women childbearing potential defined woman physiologically capable become pregnant , UNLESS meet follow criterion : ) Postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum Follicle Stimulating Hormone ( FSH ) level &gt; 40mIU/m , OR ; e ) 6 week post surgical bilateral oophorectomy without hysterectomy , OR ; f ) Are use one follow acceptable method contraception : surgical sterilization , hormonal contraception , doublebarrier method . Reliable contraception maintain throughout study 7 day study discontinuation . Subjects diagnosis psychiatric disorder major depressive disorder , bipolar disorder , obsessive compulsive disorder , generalize anxiety , dysthymia suicidality/suicide ideation Administration local anesthetic shot systemic steroid within two month screen Subjects willing undergo twoweek washout period pharmacologic nonpharmacologic pain management technique</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Pain</keyword>
	<keyword>Neuropathy</keyword>
</DOC>